Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011168 (
dysphagia
)
15,644
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Benign oesophageal strictures can arise in the treatment of oesophageal cancer as a result of radiation therapy, or at anastomotic sites, post-oesophagectomy. Data on the benefit of stenting of these types of stricture is limited. We analyzed the effects of oesophageal stents on such benign esophageal strictures. In this retrospective study, data was obtained from consecutive patients, 18 years and above from January 2000 to May 2016. Inclusion criteria comprised of oesophageal stenting in post-radiation strictures and anastomotic strictures, without any malignant residual disease. 17 patients had 22 stents inserted. 11 of these were female. 17 stents were self-expanding metallic stents (SEMS) and five were biodegradable (
BDS
). 12 strictures occurred post-radiation, while five were anastomotic strictures. Technical and clinical success rates were 100% and 86.4% respectively. Overall longterm clinical success was 45.5% (47% for
BDS
, 40% for SEMS). Minor, short-term complications, including pain and/or vomiting, were observed in 54.6% (n=12). The overall mean
dysphagia
score pre- and post-stenting was 2.95 and 1.36 (p=0.0001). Comparison of the
dysphagia
free survival for anastomotic and post-radiation strictures was statistically similar (p=0.22), as was the
dysphagia
free survival comparison between
BDS
and SEMS (p=0.055).
BDS
and SEMS are a safe and effective treatment modality for oesophageal strictures arising post-radiation or at the site of anastomoses. Retrospective study design and a low number of patients remain limiting factors of the study.
...
PMID:Oesophageal stents for the treatment of radiation and anastomotic oesophageal strictures. 3035 May 22